Schwarz Johannes
Department of Neurology, University of Leipzig, Leipzig, Germany.
Parkinsonism Relat Disord. 2007;13 Suppl 3:S466-8. doi: 10.1016/S1353-8020(08)70051-8.
"Regenerative medicine" may hopefully provide some relief or therapy for diseases which we can currently not or only barely treat. This is also true for most diseases presenting with parkinsonism, including Parkinson's disease, in spite of the available effective symptomatic treatments. The replacement of dopaminergic neurons in patients with Parkinson's disease via implantation of embryonic midbrain tissue was taken from animal experiments to clinical applications showing limited efficacy. Today, it seems possible to generate functional dopaminergic neurons from a variety of stem cells including embryonic and neural stem cells. It is not clear which tissue source will be most appropriate to test in initial clinical trials. Such cells allow for prior extensive in-vitro and in-vivo testing as well as "good manufacturing production" to reduce the risks in subsequent clinical applications.
“再生医学”有望为我们目前无法治疗或只能勉强治疗的疾病提供一些缓解或治疗方法。对于大多数表现为帕金森综合征的疾病，包括帕金森病，尽管有有效的对症治疗方法，但情况也是如此。通过植入胚胎中脑组织来替代帕金森病患者的多巴胺能神经元，已从动物实验应用于临床，但疗效有限。如今，似乎可以从包括胚胎干细胞和神经干细胞在内的多种干细胞中生成功能性多巴胺能神经元。目前尚不清楚哪种组织来源最适合在初始临床试验中进行测试。这类细胞允许进行广泛的体外和体内预先测试以及“良好生产规范”，以降低后续临床应用中的风险。
